SUTRO BIOPHARMA Business Summary

Sutro Biopharma, Inc. (STRO) operates as a clinical-stage oncology company generating revenue through a hybrid model of strategic licensing, milestone-based collaborations, and platform-access fees. The business is primarily segmented into its wholly-owned pipeline of next-generation antibody-drug conjugates (ADCs)—led by STRO-004 (Tissue Factor) and STRO-006 (Integrin beta-6)—and its extensive partnership portfolio with global pharmaceutical leaders including Astellas, Merck, and Bristol Myers Squibb. Following a late-2025 strategic pivot that externalized manufacturing and deprioritized its luvelta program, Sutro now focuses on its proprietary XpressCF cell-free protein synthesis platform to develop exatecan and dual-payload ADCs. Within the competitive landscape, Sutro competes directly with Mersana Therapeutics, Inhibrx, and Arcus Biosciences, positioning itself as a specialized platform leader capable of precise, site-specific conjugation that bypasses the limitations of traditional cell-based manufacturing. Founded in 2003 by Diego Fonstad and Stanford Professor James R. Swartz, Sutro is led by Chief Executive Officer Jane Chung, R.Ph., who assumed the role in March 2025 following her tenure as President and COO and previous leadership at AstraZeneca and Genentech. The core executive team includes Chief Financial Officer Greg Chow, Chief Scientific Officer Hans-Peter Gerber, Ph.D., and Chief Administrative Officer David Pauling. The company’s technical operations are overseen by SVP Devendra Luhar, while its strategic direction is supported by a board chaired by Connie Matsui. Sutro maintains strong institutional backing from prominent life science investors such as Samsara BioCapital, RA Capital Management, BVF Partners, and Citadel, having recently secured a $110 million equity offering in February 2026 to fund its clinical expansion.